Flow Cytometric Immune Profiling Enables Early Detection of Rejection in Islet Xenotransplantation Authors: Huu Thanh Le, Erin Fuller, Lauen Joo, Evelyn J Salvaris, Adwin Thomas, Yivee Chew, Min Hu, Francesco Ierino, Mark B Nottle, Peter J Cowan, Wayne J Hawthorne Published: 2026 ABSTRACT ABSTRACTBackgroundIslet xenotransplantation is a strategy for treatment of Type 1 Diabetes, but immune‐mediated rejection limits graft survival. This study investigated a strategy with flow cytometry–based immune monitoring to evaluate immunosuppressive therapy and provide indicators of graft rejection.MethodsPorcine neonatal islet cell clusters (NICC) from GTKO‐hCD55‐hCD59 transgenic pigs were transplanted into streptozotocin‐induced diabetic baboons (n = 10). Recipients received anti‐CD2 induction with anti‐CD154, Belatacept, and full‐dose (n = 7) or reduced/no dose Tacrolimus (n = 3). Leukocyte subsets and activation status were monitored using multiplex flow cytometry. Graft function was assessed by blood glucose measurements, porcine C‐peptide ELISA, and histological analysis.ResultsPorcine C‐peptide was detected in all recipients. Seven animals receiving full‐dose Tacrolimus maintained NICC function for up to 675 days, whereas three experienced acute rejection within two months. Flow cytometry generated absolute leukocyte counts equivalent to standard full blood counts (Deming regression slope 0.91–1.03, p<0.001), while requiring less blood (50 µl vs ∼500 µl) and processing time (50±15 vs 150±30 min). Anti‐CD2 treatment significantly reduced unoccupied surface CD2 on circulating T cells (mean 73.21%, range 55.26–91.16%, p<0.001). Long‐term graft survival was associated with greater first‐month T‐cell suppression (36.47%, 13.35–50.75%) than acute rejection (176.28%, 171.26–181.31%). Following immunosuppression withdrawal, lymphocyte counts increased by 40%–142% in all recipients. Multiplex immunofluorescence of endpoint grafts from these IS‐free animals revealed cell‐mediated destruction with increased lymphocyte infiltration and activated cytotoxic CD8+ T cells.ConclusionMultiplex flow cytometry provides a reliable method for immune monitoring in islet xenotransplantation and may help predict graft rejection.Keywords: Diabetes, flow cytometry, immunosuppression, islet cell transplantation, type 1 diabetes, xenotransplantation Introduction Type 1 Diabetes Mellitus (T1DM) is a chronic autoimmune disease characterized by the destruction of insulin‐producing beta cells of the pancreas, leading to lifelong dependency on exogenous insulin therapy for glycemic control [1]. Despite significant advancements in diabetes management, such as newer insulin analogs, insulin pumps and continuous glucose monitoring systems, individuals with T1DM still face an increased risk of severe secondary complications, including cardiovascular disease, kidney failure, and retinopathy [2, 3]. The current gold standard therapy to treat T1DM is whole pancreas or alloislet cell transplantation. However, the barrier to allotransplantation is the significant shortage of human donor organs. This presents an urgent requirement to provide an alternative source of beta‐cells for transplantation and a cure for diabetes. To address this, research efforts have focused on the use of pig organs [4]. Pigs are considered an ideal donor source for xenotransplantation due to their physiological compatibility, rapid breeding potential, and the ability to apply advanced genetic modifications to reduce organ rejection. The first pig‐to‐human heart and kidney transplant trials in living patients with survival up to nine months have laid the foundation for a promising trajectory in xenotransplantation [5, 6]. However, a major barrier to clinical xenotransplantation is the requirement of effective immunosuppression in the xenotransplant setting without severely effecting the recipient's health such as impeding wound healing, predisposing the recipient to infections or increasing their cancer risk [7]. Previously, we developed a clinically relevant immunosuppressive regimen specifically for our islet xenotransplantation program [4]. This involved induction using a novel T‐cell depleting agent, Diliximab, an anti‐CD2 monoclonal antibody [8] which has shown promise in both the murine and non‐human primate (NHP) xenotransplant settings [4, 9]. Maintenance of immune suppression was aimed at T and B cells with a short course of tacrolimus and extended treatment with Belatacept and anti‐CD154 antibody. Levels of immune suppression assessed by immune cell numbers and their activation status have been shown by others to correlate with kidney graft function and early graft rejection [10, 11]. Flow cytometry is a powerful and valuable analytical technique, used both in research and clinically to examine the complex heterogeneity and cellular interactions of immune cells, including those in transplanted patients [12, 13]. We suggest that this technique can be used to monitor the recipient's immune profile in real‐time to provide critical insights into the immune process and identify potential therapeutic targets. In this study, we present a comprehensive immune profiling of NHP recipients receiving xenoislets by utilizing flow cytometry as a monitoring tool for providing the ideal level of immune suppression. We also investigated changes in xeno‐antibody (xeno‐Abs) levels and the immune landscape at the grafted sites which correlate with graft function and delayed rejection. We highlight key findings from this preclinical model employing flow cytometry in T and B‐cell depletion strategies and outline future directions and challenges in using this approach to advance xenotransplantation as the cure for T1DM. Materials and Methods Animals Genetically modified piglets with alpha1, 3‐galactosyltransferase knockout (GTKO) and human CD55‐CD55‐H transferase (HT) genetic modification were used in this study and have been described in detail previously [4]. Baboons (Papio hamadryas) were supplied by the Australian National Baboon Colony, Sydney, Australia. This study was approved by the Animal Ethics Committees of Western Sydney Local Health District and Central Sydney Area Health District. Immunosuppression Recipient baboons were administered 5 mg/kg of anti‐CD2 monoclonal antibody (mAb) Diliximab intravenously on day ‐3 before transplantation and on the day of transplantation (day 0) and days 3, 7, and 21 post‐transplant. Additionally, anti‐CD154 mAb (20 mg/kg) and Belatacept (20 mg/kg) were administered on day 0, followed by subsequent doses on days 5, 11, 28, and every two weeks thereafter during the first six months. After six months, anti‐CD154 and Belatacept were administered monthly until withdrawn. Oral tacrolimus was given twice daily for the first four months. Tacrolimus doses were adjusted to maintain a circulating concentration of 10–15 µg/L throughout the treatment period. Porcine NICC Xenotransplantation Porcine NICC isolation and xenotransplantation into diabetic recipient baboons was performed as previously described [4]. Following six days of culture, NICCs were transplanted into the recipient's liver via the portal vein. A central line was inserted into the vena cava to facilitate post‐transplant infusion of fluids and medications and collection of blood samples. Flow Cytometry Blood was collected in EDTA tubes via central line or phlebotomy at day ‐3, 0, 3, 5, 7, 11, 14, 21, 28 then fortnightly for 6 months, then monthly until endpoint (Figure 1). For Panel 1, 50 µL of blood was added to a TruCount tube (BD, 663028) containing a cocktail of antibodies, including anti‐CD45‐BUV395, anti‐CD20‐BV421, anti‐CD3‐PE, anti‐CD14‐PE‐Cy7, and anti‐CD2‐AF647 (Table S1 and Figure 1A). For Panel 2, 200 µL of blood was mixed with anti‐CD45‐BV395, anti‐CD4‐BV510, anti‐CD3‐BV711, anti‐CD44‐BV786, anti‐CCR7‐PE, anti‐CD45RA‐PE‐Cy7, and anti‐CD8‐APC (Supplementary table 1 and Figure 2A). For Panel 3,100 µL of blood was stained with anti‐CD45‐BUV395, anti‐CD16‐BUV737, anti‐HLA‐DR‐BV421, anti‐CD11c‐BV786, anti‐CD3‐FITC, anti‐CD20‐FITC, anti‐CD14‐FITC, and anti‐CD123‐APC (Table S1 and Figure S1). After a 15‐min incubation, red blood cells were lysed with lysis buffer (BD, 555899). Cells from Panel 1 were analysed by flow cytometry using the BD Fortessa X‐20 Cell Analyzer, while cells from Panels 2 and 3 were washed with FACS buffer before flow cytometry analysis. Peripheral immune cell counts. A. Flowcytometry conducted on peripheral blood, collected from streptozotocin‐induced diabetic baboons transplanted with porcine NICC and treated with immunosuppression. B. Gating strategy for TruCount panel. C. Comparison in sample volume and processing time between FACS count and standard whole blood count by standard pathology processing, n = 270, paired t‐test. D. Linear regression analysis between cell counts from flow cytometry and standard full blood count (FBC), n = 270. E. Percentage of cell counts for different immune cell types compared to baseline cell counts, n = 10, two‐way ANOVA, mixed‐effects model with Geisser‐Greenhouse correction analysis. F‐G. Average unoccupied CD2 on T‐cells and white blood cell‐type counts at different stages of immunosuppression as compared to baseline values, n = 10, one‐way ANOVA analysis. Data presented with mean, SEM. *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001. Suppression of different T cells subtypes. A. The gating strategy for T cell subtypes and CD44 MFI. B. Percentage of cell counts for CD4+ and CD8+ T cells compared to baseline cell counts. C. Monthly CD8+/CD4+ T cell ratio. D‐E. Average cell counts and mean CD44‐BV786‐MFI in different stages of immunosuppression compared to baseline values. F‐I. Percentages of Naïve, CM, EM, and TEMRA T cells within total CD4+ or CD8+ T cells and percentages of these cell types compared to their baseline count in different stages of immunosuppression. n = 4, two‐way ANOVA, mixed‐effects model with Geisser‐Greenhouse correction analysis. Data presented with mean, SEM. *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001. Absolute count for each cell type from Panel 1 was calculated as per the formula below: Number of cells / liters = #eventsincellpopulation#eventsinabsolutecountbeadgate×#beadspertest50/1000 Hematology At blood collection, an additional 500 µL of blood was collected alongside the sample for FACS analysis. An additional sample was sent to the Westmead Institute for Clinical Pathology and Medical Research, hematology laboratory for standard whole blood cell count analysis. Immunofluorescence Liver biopsies were fixed in 10% neutral buffered formalin overnight, embedded in paraffin, and sectioned at 4 µm thickness. Dewaxed and rehydrated sections were subjected to antigen retrieval using antigen unmasking buffer (pH 9) (Vector Laboratories, H‐3301‐250) at 95°C for 30 min. Primary antibodies targeting insulin, CD3, CD20, CD4, CD8, CD11c, CD68, granzyme B, C4d and mouse anti‐ human IgG‐AF647 (see Table S1) were incubated overnight on the sections. Antigen detection was performed using anti‐guinea pig‐AF488 (Abcam, AB150185), anti‐mouse‐AF647 (Thermo Fisher, A‐21445), anti‐mouse‐AF546 (Abcam, AB 150078) and anti‐rabbit‐AF555 (Abcam, AB 150078) secondary antibodies. Sections were scanned using an Olympus VS 200 scanner and images were analysed using Olympus VS 200 software. Detection of Anti‐pig and Non‐Gal Antibodies PBMCs from outbred and GTKO pigs were incubated with 20% plasma pre‐collected from all animals for 30 min at 4°C. DAPI (Thermo Fisher, D1306) at 1:1,000 dilution was added in for 10 min labelled dead cells. Mouse anti‐IgG‐AF647 (Thermo Fisher, A‐21445) and mouse anti‐IgM‐FITC (Invitrogen, 11‐5790‐81) at 1:1000 dilution was used to label the xeno‐Abs which are bound to pig PBMCs. Cells were applied to flow‐cytometry on BD Fortessa X‐20 Cell Analyzer and data were analysed using FlowJo version 10.0. Statistical Analysis Statistical analyses were performed using GraphPad Prism (version 10), graphs were generated within the same software. Significance levels are indicated as p < 0.05 (*), p < 0.01 (**), p < 0.001 (***), and p < 0.0001 (****). Results Immunosuppression Regimen and Clinical Outcome Previously, we have reported that our first five NHP recipients transplanted with GTKO‐CD55‐CD59‐HT transgenic neonatal islet cell clusters (NICC) remained functional for up to 675 days (Table 1). In the second cohort, we modified and tested an updated immunosuppressive regimen removing Tacrolimus or replacing Tacrolimus with Sirolimus (Table 1), as Sirolimus has been demonstrated to promote T‐reg development and improve islet cell viability. TABLE 1NICC recipient's immunosuppression details and NICC survival.No.Recipient Sex (M or F) Age at Tx (Years)Immunosuppressants (IS)Survival daysPositive porcine C‐peptide daysOutcome Group1B1M3.5 Anti‐CD2, Belatacept, anti‐CD154 Full‐dose Tacrolimus 675675IS withdrawal2S1M3.5312303IS withdrawal3T1M4.1792268IS withdrawal4O1M2.5413413Euthanized due to complication5F1M3.0394182Euthanized due to complication6W1M3.5207151Inflammation‐induced rejection7B2M2.9171113Inflammation‐induced rejection8F2M2.8 Anti‐CD2, Belatacept, anti‐CD154 No Tacrolimus 165841Acute rejection9O2M5.1 Anti‐CD2, Belatacept, anti‐CD154 Reduced‐dose Tacrolimus 13629Acute rejection10P2M3.6 Anti‐CD2, Sirolimus, Belatacept, anti‐CD154 Tacrolimus till D24, then covert to Sirolimus 1849<56Acute rejection Note: B2 received a short course (3 weeks) of Sirolimus after discontinuing Tacrolimus.M: male, F: female. NICC recipient's immunosuppression details and NICC survival. Sex (M or F) Anti‐CD2, Belatacept, anti‐CD154 Full‐dose Tacrolimus Anti‐CD2, Belatacept, anti‐CD154 No Tacrolimus Anti‐CD2, Belatacept, anti‐CD154 Reduced‐dose Tacrolimus Anti‐CD2, Sirolimus, Belatacept, anti‐CD154 Tacrolimus till D24, then covert to Sirolimus Note: B2 received a short course (3 weeks) of Sirolimus after discontinuing Tacrolimus. M: male, F: female. Of the ten recipients, three underwent acute rejection, whilst seven demonstrated long‐term graft function. Two out of the seven recipients with long‐term functional grafts underwent rejection induced as a result of other inflammatory processes and two recipients were euthanized while grafts were still functional, due to complications not directly related to the immunosuppression. Immunosuppressants (IS) were completely withdrawn after more than three months of continuous insulin independence in the other three recipients. Porcine C‐peptide continued to be detected in these animals for up to 200 days following withdrawal of all immunosuppression. FACS as a Tool for Studying Immune Suppression Levels To monitor immunosuppression in the recipients, we used flow cytometry coupled with BD Trucount tubes to determine absolute counts of white blood cells in peripheral blood. On day ‐3, and on the day of transplantation (D0) and at various time points after transplantation, blood samples were collected from the recipients before performing any other procedure (Figure 1A). The populations of Trucount beads, granulocytes, monocytes, lymphocytes, B cells, and T cells in the fresh blood samples were identified by gating on forward scatter (FSC), side scatter (SSC), and markers specific for hematopoietic cells (CD45), B cells (CD20), and T cells (CD3) (Figure 1B). The absolute cell counts were calculated with quantification to the count of Trucount beads (see Method). The FACS‐based method was superior to the standard Full Blood Count (FBC) test, as it required a significantly smaller blood volume (standard 50 µl compared to an average 500 µl required for FBC test) importantly this could be collected from a small lancet skin prick rather than from venesection. It could also be done in a significantly shorter processing time (50 ± 15 min compared to 150 ± 30 min on average in FBC test) (Figure 1C). This robust method allowed us to check the recipient's immunosuppression effect and immune profiles immediately before administration of subsequent doses of immunosuppression. As such, allowing us to adjust the dose and frequency to balance between immunosuppressive efficiency and potential toxicity. More importantly we can perform this assessment at any time rather than waiting for fortnightly time points for venesection performed at the time of general anaesthesia and vessel canulation for administration of the immunosuppression. To validate the FACS method, a linear regression analysis was performed (Figure 1D), showing strong correlation with standard whole blood counts for total white blood cells, granulocytes, and lymphocytes (95% CI of regression slope: 0.9–1.1, R2 ≥ 0.8). Due to baseline variability in blood counts across recipients, cell counts were normalized to each recipient's baseline (D‐3 pre‐transplant) for comparison (Figure 1E). The level of suppression at different stages of immunosuppression was assessed by averaging cell counts across all time points within each stage (Figures 1F–G). The anti‐CD2 antibody specifically targeted the T cell population, resulting in a significant reduction in unoccupied CD2 markers on T cells three days following anti‐CD2 induction and over the duration of the first 21 days post‐transplant when anti‐CD2 was included in the immunosuppressive regimen (Figure 1G). Neutrophils and monocytes increased post‐transplant due to the healing process during the first three weeks postoperatively, despite the administration of all four immunosuppressives (Figure 1E). Following the cessation of anti‐CD2 antibody, neutrophil and monocyte counts gradually recovered, while lymphocyte populations, including B and T cells, remained significantly suppressed throughout the treatment course. Discontinuation of oral tacrolimus (TAC) after four months had minimal impact on the total white blood cell counts. After the withdrawal of all immunosuppressives, including anti‐CD154 and Belatacept, the total numbers of granulocytes and monocytes did not significantly change. Even with B cell counts increasing (p = 0.55), T cell counts remained strongly supressed, even for months following the last dose. Further analysis of the two main T cell subtypes, CD4+ and CD8+ T cells, in four recipients revealed an increase in the CD8+:CD4+ T cell ratio over the time course of the immunosuppression (Figures 2A–C). This shift was primarily due to a marked depletion of CD4+ T cells, while CD8+ T cell counts were less affected by immunosuppressant dose (Figure 2D). However, a reduction in the expression of migration marker CD44 was observed on CD4+ T cells but not on CD8+ T cells (Figure 2E). Analysis of the four main CD4+ T cell subtypes (Naïve, Central Memory (CM), Effector Memory (EM), and TEMRA) based on CD45RA and CCR7 expression revealed a decrease in the Naïve and CM populations, while the numbers of effector cell populations (EM and TEMRA) were not significantly affected (Figures 2F–G). A similar reduction was observed in CD8+ CM T cells. In contrast, TEMRA CD8+ T cells, the primary cytotoxic T cell population, increased despite immunosuppression use (Figures 2H–I). Association of T Cell Suppression and Xeno‐Abs with Short‐term NICC Survival Three out of ten recipients rejected their NICC transplant within the first two months, confirmed by the loss of porcine C‐peptide levels (Data not shown). To investigate the possible association between peripheral immune profiles, xeno‐Abs levels and resulting short‐term NICC survival, we compared immune cell counts and xeno‐Abs levels of these three recipients with the rest of the cohort, at time points before transplantation and multiple points during the first two months post‐transplantation. We observed higher immune cell counts in recipients that rejected their grafts compared with those that did not, although this difference was not statistically significant (Figure 3A). Interestingly, at one‐month post‐transplant, recipients that rejected their grafts showed significantly higher counts across all immune cell types than recipients without graft rejection (p < 0.05). However, these elevated counts returned to baseline levels during the following month and were no longer significantly different from those in recipients that did not reject their grafts. Cellular and antibody factors contributing to short‐term NICC rejection. A. Comparison of immune cell counts before transplantation, in the first month and second month between recipients with long‐term NICC function (n = 7) and those that underwent acute rejection (n = 3). B. Comparison of CD4, CD8+ T cells and effector T cells compared to baseline counts between those that rejected (n = 2) and long‐term survival (n = 2). C. Comparison of mDC:pDC in the first and second months between recipients with long‐term NICC function (n = 2) and acute rejectors (n = 2). D‐E. Levels of serum anti‐porcine IgG and IgM recipients with long‐term NICC function (n = 7) and acute rejectors (n = 3), measured as geometric median of fluorescence intensity (MFI). F‐G. Levels of serum non‐Gal anti‐porcine IgG and IgM in long‐term survival (n = 7) and rejectors (n = 3) measured as MFI. Two‐way ANOVA, mixed‐effects model, data was presented with mean, SEM. *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001. Analysis of CD4+ and CD8+ T cells, as well as effector T cells, in two long‐term survivors and two recipients that rejected their grafts during the first month post‐transplant revealed that T cell populations, particularly CD8+ T cells and CD8+ effector cells, remained higher in the graft rejection group, indicating ineffective depletion. In contrast, T cell counts in the long‐term survivors were significantly reduced compared with baseline levels. (Figure 3B). A high pre‐transplant mDC:pDC ratio and an increase in CD16+ mDCs have been associated with graft rejection in clinical liver, heart, and intestinal transplants [14, 15, 16]. In this study, analysis of peripheral dendritic cells (DCs) in long‐term survivors and acute rejectors also revealed a higher mDC:pDC ratio in the subset that rejected their grafts before and within the first month post‐Tx (Figure S3, Figure 3C). An increase in CD16+ mDCs was also observed in those that rejected their grafts, while the percentage of CD16+ mDCs decreased in long‐term survivors (Figure S2). To investigate the effect of xeno‐Abs on survival outcomes of grafted islets, we compared anti‐porcine IgG and IgM levels between the long‐term survivors and those that rejected their grafts. We observed significantly higher levels of anti‐pig IgG and IgM in those that rejected their grafts before transplantation and in the first month post‐transplant as compared to the recipients with long‐term NICC function (Figures 3D–E). As our porcine donors do not express Galactose α1‐3 galactose, a major xeno‐antigen, we also compared the non‐Gal anti‐pig antibodies in the two groups of recipients. In contrast to total anti‐porcine Abs, we observed no significant difference of non‐Gal anti‐porcine Abs between the groups (Figure 3.F–G). Continuation of Long‐term NICC Function Despite Withdrawal of IS Among the ten recipients with long‐term functional NICCs grafts, three (S1, B1 and T1) had their immunosuppression withdrawn before reaching the one‐year endpoint. In two recipients (S1 and T1), functional NICCs persisted for around 2 months before graft loss from rejection. One recipient (B1) maintained detectable levels of porcine C‐peptide until endpoint (>200 days following withdrawal of all immunosuppression), although peak values at IVGTTs gradually reduced over time [4]. This suggested delayed rejection in this recipient (B1) as compared to the others. To investigate the mechanism of IS‐free graft rejection, we compared immune cell counts before and after withdrawal of the remaining two immunosuppressives (anti‐CD154 and Belatacept). We found increased levels of both B and T cells following the IS withdrawal (Figure 4A). We also observed a slight increase in anti‐porcine IgG and IgM in all recipients after withdrawal of all immunosuppression (Figure 4B) Figure elucidating some of the immune factors responsible for NICC rejection after withdrawal of all immunosuppressants (IS). A. Immune cell counts before and after withdrawal of all immunosuppression, compared to baseline. B. Xeno‐Abs levels before and after withdrawing immunosuppression. C. Fluorescent staining for NICC (insulin), T cells (CD4+ and CD8+), B cells, macrophages, DCs infiltration and Granzyme‐B, IgG and C4d in biopsied tissue and endpoint‐tissue. D. Quantitative comparison of immune cell infiltrations in biopsied tissues (17 Regions of Interest‐ROI) and end‐point tissue (144 ROI). Welch's t test, data is presented with mean, SEM. *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001. E. Proportion of NICC‐infiltrating immune cell types in IS‐free endpoint grafts. To examine potential changes in immune cells at the graft site, we performed biopsies and evaluated histology and immunofluorescence in liver tissue sections collected at the four‐month time point, while recipients were still receiving anti‐CD154, Belatacept, and oral Tacrolimus, as well as at the study endpoint. At the fourth month post‐Tx, we observed limited infiltration of T cells, B cells, macrophages and DCs. There was also the presence of some T cells surrounding but not infiltrating the islets of some islet cell clusters (Figure 4C). By contrast, significant increases in infiltration of all immune cell types were observed in and around the islets at the end‐point biopsies (Figures 4C‐D) following withdrawal of all immunosuppression. We did not observe depositions of IgG nor C4d, which are markers of antibody‐facilitated graft rejection, in any of the biopsies or end‐point samples (Figure 4C). There was also a significant increase in Granzyme B within the islets, mostly co‐located with T cells (Figures 4C–D). T cells, CD8+ T cells in particular, accounted for the majority of NICC‐infiltrated immune cells (35%) (Figure 4E), while macrophages were also prominent (29%). Discussion Flow Cytometry Is a Useful Tool to Monitor Immunosuppression and Provide a Potential Tool to Prevent Acute Rejection of Xenoislet Transplants Flow cytometry is a powerful tool for analyzing blood immune cell phenotypes, as it allows for the simultaneous detection of multiple membrane‐bound and intracellular markers on live cells with a relatively small amount of fresh blood. The Human Immune Phenotyping Consortium (HIPC) has published five eight‐color panels to assess a variety of blood immune cells, which have been applied in immune profiling of healthy human populations, along with the diagnosis of leukemia and lymphoma, and also in limited settings selecting transplant recipients, monitoring immunosuppressant treatment, and assessing outcomes in kidney, heart, and liver transplantation [17, 18, 19, 20, 21, 22]. Standardised flow cytometry for islet allotransplantation has also been developed, with eight panels covering 46 immune cell markers to accurately quantify and characterize most major immune cell types in fresh blood from transplant recipients before and up to 26 months following transplantation [23]. As yet a flow cytometry panel does not exist to assess immune responses in baboon recipients of xenoislet grafts. Therefore, we have developed three flow cytometry panels for absolute counts of major immune cell types, T cell and dendritic cell (DC) phenotyping, closely aligning with the standard HIPC panels and those used in clinical islet allotransplantation. Most of the antibodies in our panels were designed for human cells but they cross react with baboon cells due to the high genomic and haematological homology between the two species [24]. This similarity in immune cell markers supports the translational potential of this method for xenogeneic islet cell transplantation and supports the clear translation of these flow cytometry panels from baboon to human clinical trials. With the absolute counts of major immune cells, specifically T and B cells, and the relative quantification of CD2 markers, we were able to closely assess the effect of immunosuppression in baboons receiving NICC xenotransplants. Currently, Antithymocyte Globulin (ATG) including TAGAM (equine‐derived) and Thymoglobulin (rabbit‐derived) are the only two FDA‐approved induction immunosuppressive agents used for depletion of T cells pretransplant [25]. ATG, a polyclonal antibody, has been shown to also bind to different cell types [26] causing off target effects such as haemolysis, thrombocytopenia and serum sickness [27]. Also, previous clinical studies have shown ATG induction led to late‐stage differentiated CD8+ T cells and is associated with immune activation in patients [28]. In contrast to this CD2, which is a transmembrane glycoprotein and co‐stimulatory receptor found on the surface of T cells and Natural Killer (NK) cells, presents a more specific target for T cell depleting drugs. Specifically, siplizumab (TD601, ITB‐Med LLC), a humanised anti‐CD2 monoclonal Ab is currently being investigated in multiple Phase II trials for renal transplantation, including induction therapy and tolerance‑induction regimens [29]. Our chimeric anti‐CD2 Ab monoclonal diliximab has been previously shown to deplete human and cynomolgus monkey T cells without immune activation or cytokine release in chimeric mice [30]. Diliximab's broad recognition of CD2 from New World monkeys, Old World monkeys and human make it a potentially potent induction reagent in both research and clinical transplantation [30]. In this study, we verified the specificity and safety of diliximab, which had a strong and prolonged depleting effect most importantly it was only targeted T cells with no off‐target effects seen. A major animal ethics advantage of this approach is the substantial reduction in the need for repeated venesection procedures performed under general anesthesia for longitudinal immune monitoring. This represents a significant animal welfare benefit, as comprehensive immune profiling can be performed using only 50 µL volume of blood obtained from a lancet prick sample (e.g., from a digit or the baboon bottom), rather than requiring sedation or general anesthetic for venous blood collection and the minimum sample volume of the 500–1,000 µL typically needed for conventional immunological assays. This ten‐twenty fold reduction represents a meaningful refinement in the use of NHP models, particularly in studies requiring intensive longitudinal sampling, by reducing sampling‐related burden and potentially enabling less invasive capillary collection. This may also reduce reliance on blood collection during scheduled procedures requiring general anaesthesia or vascular access, thereby providing substantial animal‐welfare benefits. Beyond its technical advantages, the low‐volume requirement also enhances translational relevance, as frequent immune monitoring may be more readily implemented in clinical settings when only minimal blood volumes are required. Association of Immunosuppression Effect and Xeno‐Abs Levels with Long‐term Graft Survival We investigated the correlation between the level of immune suppression and acute NICC xenograft rejection which occurred within the first three months post‐transplant. Chrilla et al. (2025) studying 28 pediatric kidney transplant cases induced with rTAG observed no difference in clinical outcome between patients with CD3+ T cell count < 25 cells/mm3 (or < 50% of normal range) and those with less suppressed T cell counts [31]. The authors suggested T cell monitoring may not be necessary during the induction therapy period. However, another study of a larger cohort (71 kidney transplants) by Eyvaz et al. (2025) showed clearly that higher CD3+ T cell numbers significantly correlated with acute rejection [10]. In addition, Zhou et al. (2025) counted various WBC types before and seven days after kidney transplant in 217 patients and showed depleted helper T cells (CD3+ CD4+) and elevated cytotoxic T cells (CD3+CD8+) were linked with delayed kidney function [11]. In liver transplantation, expansion of memory CD8+ T cells with increased levels of IFN‐γ and IL‐17 also correlates strongly with acute rejection [32]. There is limited information about the immune suppression level and clinical outcome in alloislet transplantation. However, a study on porcine islet xenotransplantation in rhesus monkeys showed a strong correlation of reduced CD4+/CD8+ cell ratios with early‐rejected grafts within the first two months post‐transplant [33]. This ratio reduction was due to the expansion of CD8+ effector memory T cells (TEM) [33]. In our study, we observed a positive correlation between the levels of immune suppression, especially in the first month after transplant, with engrafted NICC survival. In long‐term recipients, T cell counts following induction and in the subsequent two months after transplantation were less than 50% of pre‐suppression levels. We also observed elevation of CD8+ effector T cells but not CD4+ effector T cells in acute‐rejecting recipients. These results, together with prior observations in the allotransplantation setting, highlight the importance of monitoring T‐cell suppression during and immediately after transplantation. The flow cytometry approach presented in this study provides a practical means of monitoring not only T‐cell suppression but also the broader peripheral immune profile in real time. These findings raise the possibility that longitudinal immune profiling could identify immune signatures or biomarkers associated with acute graft rejection, potentially enabling more timely adjustment of immunosuppressive therapy. However, larger prospective studies would be required to validate such biomarkers and determine their predictive value in xeno‐islet rejection. Pre‐formed anti‐porcine antibodies have been shown to be a primary trigger of hyperacute rejection and contributing factor for subsequent chronic rejection in xenotransplantation [34, 35, 36, 37, 38]. Anti‐Gal Abs account for the majority of anti‐porcine Abs which are naturally present in human and NHP blood [39]. In this study, NICCs derived from transgenic pigs lacking the Gal antigen and expressing the complement regulators CD55 and CD59 were used. These genetic modifications, in combination with immunosuppressive therapy, prevented hyperacute rejection in all recipients. Recipients who experienced acute rejection exhibited significantly higher levels of preformed anti‐porcine IgG and IgM compared with those with longer‐term graft function, whereas no significant difference was observed in non‐Gal anti‐porcine antibodies between the two groups. Given that the transplanted islets expressed a GTKO genotype, these findings are consistent with a limited contribution of Gal‐specific humoral responses. However, other porcine‐specific antigens may also contribute to the elevated anti‐porcine IgG and IgM levels observed in recipients experiencing acute rejection. These include, but are not limited to, Neu5Gc, Sda‐like glycans, and swine leukocyte antigens (SLA), which have been implicated as xeno‐antigens in cross‐species transplantation [40]. Li et al. (2021) reported increased anti‐pig IgG, IgM, IgE and IgA levels in sensitised baboons but not in non‐sensitised ones with various pig xenografts [41]. Kang et al. reported that only 46.7% of xenoislet recipients with long‐term graft function (> 1 month) experienced an increase of anti‐Gal IgG post‐transplants and suggested these animals were partially suppressed with anti‐CD154 and sirolimus [42]. Our recipients were not sensitised and did not show any significant increase of anti‐Gal IgM or IgG regardless of NICC survival outcomes. This result suggests that our immunosuppression maintenance using anti‐CD154, Belatacept and oral tacrolimus was sufficient to prevent the elevation of xeno‐Abs. CD8+ T Cells Eventually Mediates Rejection in Long‐term NICC Recipients Following Withdrawal of all IS Due to the undesired side effects of chronic IS on graft function and the ongoing long‐term risk to the patient in regard to potential infection and malignancy, efforts to achieve immune tolerance in which graft function remains in the absence of all IS have been studied with limited success. Immune tolerance can be induced by pre‐conditioning recipients with hematopoietic bone marrow cells from donors before transplantation [43, 44, 45]. This process, though, requires extensive operation with risk of life‐threatening graft‐versus‐donor disease. Liu et al. (2007) reported a case of alloislet transplanted NHP, induced with ATG and anti‐CD20 (rituximab) to deplete both T and B cells, resulting in drug‐free graft tolerance for more than a year [46]. To test if our recipients could achieve immune tolerance, we withdrew all IS in three recipients with long‐term graft function (S1‐143 days, T1‐200 days and B1‐286 days). These recipients remained normoglycemic for up to three months before eventual graft rejection. This is consistent with results from a clinical report by Markmann et al. (2024) who failed to replicate immune tolerance in most transplant recipients induced with ATG and rituximab [47]. The authors observed that peripheral B cells in these patients return to pre‐suppression levels but were dominated by naïve B cells. By contrast, T cells rebounded with the majority of effector cells (TEM as TEMRA). Baeten et al. (2006) also showed significant increase in central memory and a decrease in effector CD8+ T cells in drug‐free tolerant patients compared to ones with chronic rejection [48]. Similarly, in our long‐term graft recipients that were IS‐free we observed a gradual increase of lymphocytes (both B and T cells) as well as non‐Gal Abs in all three recipients. Noticeably, we observed the gradual recovery of CD8 T cells and an increase in the proportion of effector CD8+ T cells (TEMRA) in all recipients, despite the use of IS and independent of graft survival. Compared to the biopsies taken when the recipients were on IS drugs, graft tissue obtained at end point showed significant destruction of the porcine NICC xenotransplant with elevated infiltration of T cells, especially cytotoxic Granzyme+ CD8+ T cells. There was a large proportion of infiltrating macrophages, along with liver‐resident Kupffer cells which may play role in cleaning up cell debris as the result of porcine islet killing. These findings together with the absence of antibody and C4d deposition at the graft site suggest eventual T‐cell mediated destruction of the porcine NICC xenotransplant in these long‐term recipients following withdrawal of all immunosuppression. We acknowledge the limited sample size (n = 10) in this study, but this reflects the complex nature of non‐human primate research and the requirement for long‐term monitoring of recipients over several years following xenogeneic islet transplantation. As this project progresses, we aim to expand the cohort and report findings from a larger sample size in future studies. This study primarily focuses on the application of flow cytometry for real‐time immune phenotyping and characterization of immune cell profiles in xeno‐islet transplant recipients. Future studies can also investigate functional immune responses, including T‐cell cytokine production and donor‐specific reactivity, that could complement the extensive phenotypic data presented here. They may be able to provide further insight into the functional status of the immune response. Our study also did not investigate peripheral NK cells which have also been shown to be strongly involved in graft rejection [49, 50]. This was due to the lack of NK‐cell specific markers for NHPs. These have previously been reported to have low expression of CD56, a specific marker for human NK cells [51]. However, a recent study by Gunes et al. (2024) has validated a flow cytometry panel to detect and monitor immune profiles in xenotransplanted baboons which will allow us to re‐visit this cohort along with future xenotransplant studies [52]. Our study highlights multiplex flow cytometry is a powerful and rapid platform for real‐time monitoring of immune dynamics in islet xenotransplant recipients. When integrated with complementary analytical approaches, this strategy revealed a clear association between effective immunosuppression and prolonged survival of porcine islet xenografts. Notably, the expansion of peripheral CD8+ effector T cells and their predominance within islet graft infiltrates in immunosuppression‐free recipients indicates that cytotoxic T cell–mediated responses are a key driver of late graft rejection despite initial long‐term survival. Collectively, our data demonstrate that durable control of T‐cell–mediated immunity is a prerequisite for maintaining xenogeneic islet integrity. These findings support the need for balancing sufficient T‐cell suppression to stabilize immune homeostasis and sustain long‐term graft function, while raising an important translational question regarding the minimum degree of T‐cell control required for graft protection. Given the potential direct adverse effects of calcineurin inhibition on beta‐cell/islet viability and function, the optimal maintenance regimen should balance adequate T‐cell suppression with preservation of graft health. Thus, rather than supporting the continued use of tacrolimus specifically, our findings provide a rationale for maintaining effective T‐cell control while identifying immunosuppressive approaches that minimize unnecessary exposure and potential compromise of islet function. This work defines a practical and biologically grounded need for a minimum level of immunosuppression, advancing xenotransplantation from experimental feasibility toward durable clinical reality. Author Contributions Conceptualization: Wayne J Hawthorne, Peter J Cowan, Mark B Nottle. Islet isolation and transplantation: Wayne J Hawthorne, Evelyn J Salvaris, Erin Fuller, Huu Thanh Le. Blood collection. Wayne J Hawthorne, Erin Fuller, Huu Thanh Le. Perform flow cytometry: Adwin Thomas, Lauen Joo, Huu Thanh Le, Yivee Chew, Min Hu. Perform ELISA, IHC, IF: Huu Thanh Le Data curation, analysis and visualization: Huu Thanh Le Funding acquisition: Wayne J Hawthorne, Peter J Cowan, Mark B Nottle. Supervision: Wayne J Hawthorne. Writing – original draft: Huu Thanh Le and Wayne J Hawthorne. Writing – review and editing: Huu Thanh Le, Wayne J Hawthorne, Evelyn J Salvaris, Peter J Cowan. Conflicts of Interest The authors declare no conflicts of interest. Supporting information Supporting Information: xen70170‐sup‐0001‐SuppMat.docx Supporting Information: xen70170‐sup‐0002‐SuppMat.docx Acknowledgments This work was supported by grants from Breakthrough T1D (formerly JDRF) Grant #3‐SRA‐2023‐1418‐S‐B and NH&MRC Australia—Application ID: APP1156889 and 2038096 Open access publishing facilitated by The University of Sydney, as part of the Wiley ‐ The University of Sydney agreement via the Council of Australasian University Librarians Data Availability Statement All data needed to evaluate and reproduce the conclusions in the paper are present in the paper and the Supplementary Materials. The materials developed in this study are available upon request. References Associated Data Supplementary Materials Supporting Information: xen70170‐sup‐0001‐SuppMat.docx Supporting Information: xen70170‐sup‐0002‐SuppMat.docx Data Availability Statement All data needed to evaluate and reproduce the conclusions in the paper are present in the paper and the Supplementary Materials. The materials developed in this study are available upon request.